Influence of IFN-gamma and its receptors in human breast cancer.
BACKGROUND
Interferons are a group of proteins that trigger multiple responses including prevention of viral replication, inhibition of cell growth, and modulation of cell differentiation. In different mammary carcinoma cell lines IFNgamma induces growth arrest at mid-G1. At the present there are no in vivo studies in human breast. The aim of this study was to investigate the expression patterns of IFNgamma and its two receptors (IFNgamma-Ralpha and IFNgamma-Rbeta) by Western blot and immunohistochemistry, in order to elucidate its role in the different types of human breast cancer (in situ and infiltrative).


METHODS
Immunohistochemical and semiquantitative study of IFNgamma, its receptors types (IFNgamma-Ralpha and IFNgamma-Rbeta), cell proliferation (proliferating cell nuclear antigen, also named PCNA), and apoptosis (TUNEL method) was carried between the three breast groups (fibrocystic lesions, in situ tumors and infiltrating tumors).


RESULTS
In the three groups of patients, IFNgamma and IFNgamma-Ralpha immunoreactions appeared in the cytoplasm while IFNgamma-Rbeta also was found in the nucleus. The optical density to IFNgamma was higher in in situ carcinoma than in benign and infiltrating tumors. When we observed IFNgamma-Ralpha, the optical density was lower in infiltrating carcinoma than in benign and in situ tumors (the higher density). To IFNgamma-Rbeta, the optical density was similar in the three group samples. In tumor samples PCNA and TUNEL index was significantly higher; than in benign diseases. PCNA index increased with the malignance. No significant differences were found between cancer types to TUNEL. IFNgamma could be a potential therapeutic tool in breast cancer. However, tumor cells are able to escape from the control of this cytokine in the early tumor stages; this is probably due to a decreased expression of IFNgamma, or also to an alteration of either its receptors or some transduction elements.


CONCLUSIONS
We conclude that the decrease in the % positive samples that expressed IFNgamma and IFNgamma-Ralpha together with the nuclear localization of IFNgamma-Rbeta, could be a tumoral cell response, although perhaps insufficient to inhibit the uncontrolled cell proliferation. Perhaps, IFNgamma might be unable to activate p21 to stop the cell cycle, suggesting a possible participation in breast cancer development.
García-Tuñón
Ignacio
I
Department of Cell Biology and Genetics, University of Alcalá, E-28871, Alcalá de Henares, Madrid, Spain. ignacio.tunon@uah.es.
Ricote
Mónica
M
Ruiz A
Antonio
A
Fraile
Benito
B
Paniagua
Ricardo
R
Royuela
Mar
M
D000328:Adult; D000368:Aged; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D049109:Cell Proliferation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000378:metabolism*; D008875:Middle Aged; D017471:Receptors, Interferon / Q000378:metabolism*; D000096743:Interferon gamma Receptor
D007371:Interferon-gamma; D017471:Receptors, Interferon; D000096743:Interferon gamma Receptor
Breast Cancer Res Treat. 1991 Aug;18(3):165-70
1756259
Int J Cancer. 1998 Jul 3;77(1):138-45
9639405
EMBO J. 1999 Mar 1;18(5):1223-34
10064589
Eur J Cancer. 1996 Dec;32A(13):2312-8
9038615
Zhonghua Nan Ke Xue. 2005 Jun;11(6):448-51, 454
15999492
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2217-24
15598783
Ann Surg. 2001 May;233(5):623-9
11323500
Int J Cancer. 1998 May 4;76(3):423-9
9579582
Histopathology. 2005 Jul;47(1):82-9
15982327
Cancer Res. 2000 Oct 15;60(20):5673-80
11059759
Clin Cancer Res. 2005 Oct 15;11(20):7545-53
16243830
Eur Cytokine Netw. 2000 Mar;11(1):119-27
10705309
J Interferon Cytokine Res. 2001 Nov;21(11):951-9
11747627
Cell. 1988 Oct 21;55(2):273-80
2971451
Immunity. 1994 Sep;1(6):447-56
7895156
Cancer Res. 2003 Oct 1;63(19):6424-31
14559832
J Surg Res. 1996 Jul 15;64(1):68-74
8806476
Cancer Sci. 2006 Oct;97(10):1044-9
16984377
Eur J Cancer Clin Oncol. 1986 Apr;22(4):419-26
3089802
Cancer Res. 1990 Jun 15;50(12):3473-86
1692761
Cell. 1994 Mar 11;76(5):803-10
8124717
Cell Growth Differ. 2000 Jun;11(6):335-42
10910100
Br J Cancer. 1993 Aug;68(2):352-6
8347490
Cancer Invest. 1995;13(2):165-72
7874570
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205
8108387
Cell. 1994 Mar 11;76(5):793-802
8124716
Biochem J. 2002 Aug 1;365(Pt 3):825-32
11936954
Cancer Lett. 2003 Jun 10;195(2):201-10
12767529
Oncogene. 1999 Jun 24;18(25):3725-36
10391680
Cancer Invest. 2006 Mar;24(2):119-25
16537179
Cell Growth Differ. 1996 Mar;7(3):289-300
8838859
Cancer. 1984 Feb 1;53(3 Suppl):783-9
6198060